Myocardial Infarction Global Market Report 2024

The myocardial infarction market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The expansion observed in the historical period can be attributed to several factors, including the introduction of beta-blockers, the establishment of chest pain centers, the implementation of thrombolytic therapies, advancements in genomic and personalized medicine approaches, and the integration of wearable cardiovascular devices.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be linked to various factors, including global health initiatives aimed at enhancing cardiovascular health, increased accessibility to reperfusion therapies, the emergence of RNA therapeutics for cardiovascular diseases, the adoption of patient-centered care models, a heightened focus on addressing microvascular dysfunction, and the development of bioelectronic medicine. Major trends expected in the forecast period encompass advancements in cardiovascular imaging, innovations in cardiac surgery techniques, progress in telemedicine, the integration of artificial intelligence for diagnosis, the introduction of digital biomarkers for risk prediction, the utilization of blockchain for healthcare data security, AI-driven drug discovery, and the ongoing innovations in cardiac rehabilitation technologies.

The anticipated growth of the myocardial infarction market is expected to be driven by an increasing number of smokers. Individuals who engage in smoking, whether through cigarettes, cigars, or pipes, expose themselves to chemicals present in tobacco smoke. These substances have the potential to thicken and clot the blood in veins and arteries, leading to blockages that can result in myocardial infarction. A notable example is the data from the UK-based Office for National Statistics in September 2023, revealing that the segment of the UK population aged 25 to 34 years had the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This marked an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Consequently, the growing number of smokers is a significant factor propelling the growth of the myocardial infarction market.

The rising incidence of cardiovascular diseases is expected to contribute to the expansion of the myocardial infarction market. Cardiovascular diseases, a category of disorders affecting the heart and blood vessels, prompt the utilization of myocardial infarction drugs to manage and treat the aftermath of heart attacks. According to the World Heart Federation in October 2022, the number of cardiovascular disease (CVD) deaths is projected to increase from an estimated 18.9 million in 2020 to over 22.2 million in 2030. This upward trend in cardiovascular diseases further underscores the driving force behind the growth of the myocardial infarction market.

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.


Major companies in the myocardial infarction market are focused on developing advanced devices that utilize technology, such as SmartAssist dual-sensor technology, to address acute right heart failure and to maximize their profits in the market. SmartAssist dual-sensor technology refers to a system equipped with two sensors designed to gather and monitor advanced metrics in a medical device. For instance, in October 2022, Abiomed, a US-based provider of medical technology, received FDA approval for its Impella RP Flex with SmartAssist. It is implanted via the internal jugular vein; it allows patient mobility and features dual-sensor technology for optimal patient management and weaning. The Impella RP platform includes percutaneous right heart mechanical circulatory support technologies designed for native heart recovery. Impella RP with SmartAssist has received approval from the U.S. FDA for the treatment of right heart failure or decompensation after procedures including left ventricular assist device implantation, myocardial infarction, and heart transplant.

In December 2022, Johnson & Johnson, a leading US-based healthcare products conglomerate, finalized the acquisition of Abiomed for a notable sum of $16.6 billion. This strategic acquisition positions Johnson & Johnson MedTech to integrate heart recovery solutions from Abiomed into its existing Biosense Webster electrophysiology division. By doing so, Johnson & Johnson aims to augment its offerings in the rapidly growing cardiovascular sector. Abiomed, renowned for its pioneering clinical research, specializes in the treatment of acute myocardial infarction, further enriching Johnson & Johnson's comprehensive cardiovascular solutions portfolio.

Major companies operating in the myocardial infarction market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Bio-Rad Laboratories Inc., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Dynavax Technologies Corp, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS.

North America was the largest region in the myocardial infarction market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Within the realm of myocardial infarction treatment, various drug classes play pivotal roles in managing and mitigating the condition's impact. These encompass antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents specifically target the prevention of blood clot formation by inhibiting platelet aggregation. Available in both oral and injectable formulations, these agents are accessible through a diverse range of distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

The myocardial infarction market research report is one of a series of new reports that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.